|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-5-25
|
|
pubmed:abstractText |
Docetaxel (DXT) is an anticancer agent that has demonstrated therapeutic efficacy against solid tumors, particularly breast cancer. Based on the use of hematopoietic stem cell (HSC) transplantation to restore hematopoietic reconstitution after myeloablative therapy, this study was performed to determine if DXT could mobilize HSCs in vivo.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
451-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10781903-Animals,
pubmed-meshheading:10781903-Cell Count,
pubmed-meshheading:10781903-Cell Division,
pubmed-meshheading:10781903-Colony-Forming Units Assay,
pubmed-meshheading:10781903-Dose-Response Relationship, Drug,
pubmed-meshheading:10781903-Female,
pubmed-meshheading:10781903-Flow Cytometry,
pubmed-meshheading:10781903-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:10781903-Leukocyte Count,
pubmed-meshheading:10781903-Leukocytes, Mononuclear,
pubmed-meshheading:10781903-Mice,
pubmed-meshheading:10781903-Mice, Inbred C57BL,
pubmed-meshheading:10781903-Paclitaxel,
pubmed-meshheading:10781903-Spleen,
pubmed-meshheading:10781903-Taxoids
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Bone Marrow Transplantation Program, Georgetown University Medical Center, Washington, DC 20007, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
